assay menu

  • Prepare your lab for a high volume of respiratory tests with a streamlined multiplex test. With a single-step solution, your lab will easily adapt to increased demand this flu season could bring. The QIAstat-Dx panels redefines ease-of-use with less than one-minute hands-on time and a seamless sample to result workflow.

    With the QIAstat-Dx Panels:

    • Save time – all reagents are preloaded into the cartridge
    • Reduce errors – tests are performed on a single instrument solution
    • Lower costs – cartridges are shipped and stored at room temperature

  • QIAstat-Dx Respiratory Panel

    True Sample to Insight solution for patients with suspected upper respiratory infections. Detects 20 viral and bacterial targets in about an hour.

    Download the flyer

    Get product information

  • QIAstat-Dx Respiratory SARS-CoV-2 Panel

    (Emergency Use Authorization)

    This expanded version of our multiplex respiratory cartridge detects and differentiates* 21 viral and bacterial respiratory targets, including SARS-CoV-2 to support efforts to provide accessible testing to meet the demands of the COVID-19 outbreak.

    Download the flyer

    Get product information and resources

    *Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Be the first to know about QIAstat-Dx news and webinars

Send me updates
The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declarations is terminated or authorization is revoked sooner.
  • Social Sharing